A group of UK academics have broadly welcomed the fund that will pay for innovative non-cancer drugs, but have expressed concern over issues such as the entry criteria and the definition of “high unmet need.” They also say safeguards are needed against possible financial loss to the National Health Service.
England’s Innovative Medicines Fund has come in for more criticism, this time from a group of London-based academics who say that the entry criteria for the fund are “lacking in detail” and that the longer timeframes for gathering more evidence on a new drug could discourage manufacturers from providing the necessary data in the first place.
They also suggest that the IMF, like the Cancer Drugs Fund (CDF) on which it is broadly modeled, should be...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
